Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.

Cancer research - 6 Jun 2022

Pfeiffer Anamarija, Franciosa Giulia, Locard-Paulet Marie, Piga Ilaria, Reckzeh Kristian, Vemulapalli Vidyasiri, Blacklow Stephen C, Theilgaard-Mönch Kim, Jensen Lars J, Olsen Jesper V

Abstract excerpt

The protein tyrosine phosphatase SHP2 is crucial for oncogenic transformation of acute myeloid leukemia (AML) cells expressing mutated receptor tyrosine kinases. SHP2 is required for full RAS-ERK activation to promote cell proliferation and survival programs. Allosteric SHP2 inhibitors act by stabilizing SHP2 in its autoinhibited conformation and are currently being tested in clinical trials for tumors with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Piperidines

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Pyrimidines

Share to Tyrosine

Source

Open in PubMed Open full text

Identifiers

PMID: 35311954
DOI: 10.1158/0008-5472.CAN-21-0548
PMCID: PMC9177641

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.PMID 35311954Read ↗

A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug ResistanceSemantic proximity Read ↗

A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance.Semantic proximity Read ↗

A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug ResistanceSemantic proximity Read ↗

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations.Semantic proximity Read ↗

JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibitionSemantic proximity Read ↗

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in <i>FLT3-</i> and <i>KIT-</i> Mutant AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.